Wolfe Research on Protagonist Therapeutics (PTGX): 'We forecast peak sales of $2.9B in 2036'
Tweet Send to a Friend
Wolfe Research analyst Alexandria Hammond reiterated an Outperform rating and $225.00 price target on Protagonist Therapeutics (NASDAQ: PTGX).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
